In Russia have developed a drug to treat spinal muscular atrophy, it will lead the market in 2026. It is reported RIA Novosti with reference to the statement of the Ministry of industry and trade.
“A domestic manufacturer of pharmaceuticals, ZAO “Biocad” developed a gene-therapy drug for medical use designed for treatment of spinal muscular atrophy”, — stated in the message Department signed by the Minister Denis Manturov.
To ensure drug to needy patients, the company requires state support for a financial and organizational nature.
Currently under preclinical testing of drugs to determine effective and safe doses for humans. Apply for clinical trials planned for this year. “The drug potentially capable of providing long-term or even lifelong effects, fully restoring gene function”, — explained in the Ministry of industry.
Spinal muscular atrophy develops due to the destruction of the alpha motor neurons responsible for contraction of skeletal muscles located in the anterior horns of the spinal cord.
Until the end of 2024 Russia will be the national project “Health”. In total it is planned to spend more than 1.7 trillion rubles. The project aims to provide Russians with affordable health care and improving its quality, the changing nature of relations between doctors and patients, increasing to 70 percent coverage of primary prevention, introduction of modern clinical guidelines, reducing mortality from cardiovascular and oncological diseases, increase in life expectancy of Russians at the age of 78 and more.
Video, photo All from Russia.